Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Acq. announced
Inv. presentation
Mirum Pharmaceuticals, Inc. (MIRM) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
10/13/2023 8-K Quarterly results
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update - $37.5 million total revenue, including net product sales for LIVMARLI ® oral solution of $32.5 million, for second quarter 2023 - Acquiring CHENODAL ® and CHOLBAM ® , advancing Mirum’s leadership in pediatric hepatology with a multi-product franchise - Four late-stage clinical trial data readouts expected later this year - Conference call to provide business updates today, August 3 at 1:30 p.m. PT/4:30 p.m. ET"
07/17/2023 8-K Quarterly results
06/08/2023 144 Form 144 - Report of proposed sale of securities:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update - $31.6 million total revenue, including net product sales for LIVMARLI ® oral solution of $29.1 million, for first quarter 2023 - Conference call to provide business updates today, May 4 at 1:30 p.m. PT/4:30 p.m. ET"
05/03/2023 144 Form 144 - Report of proposed sale of securities:
05/03/2023 SC 13G/A Flynn James E reports a 0% stake in Mirum Pharmaceuticals, Inc.
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2023 8-K Quarterly results
04/14/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
04/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/10/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/08/2023 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI ® oral solution totaled $75.1 million for first full fiscal year of U.S. commercial launch, and full year 2022 revenue totaled $77.1 million - Conference call to provide business updates today, March 8 at 1:30 p.m. PT/4:30 p.m. ET"
03/08/2023 SC 13G/A BlackRock Inc. reports a 4.6% stake in Mirum Pharmaceuticals, Inc
02/14/2023 SC 13G/A Rock Springs Capital Management LP reports a 4.9% stake in Mirum Pharmaceuticals, Inc.
02/14/2023 SC 13G EVENTIDE ASSET MANAGEMENT, LLC reports a 5.6% stake in Mirum Pharmaceuticals, Inc.
02/10/2023 SC 13G/A Flynn James E reports a 5.5% stake in Mirum Pharmaceuticals, Inc.
02/03/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/09/2023 8-K Quarterly results
12/19/2022 8-K Quarterly results
12/13/2022 8-K Quarterly results
12/01/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/29/2022 8-K Quarterly results
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
09/12/2022 SC 13G/A Flynn James E reports a 5.5% stake in Mirum Pharmaceuticals, Inc.
09/09/2022 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy